Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI

NCT02843230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-04-08

No results posted yet for this study

Summary

This research study aims to predict treatment response to anti-angiogenic therapy (Avastin) using advanced magnetic resonance imaging (MRI) and spectroscopy (MRS) for Glioblastoma patients.

Conditions

Interventions

RADIATION

Avastin

RADIATION

Lomustine

RADIATION

Temozolomide

DEVICE

MRI

DEVICE

MRS

DEVICE

DSC

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Eva-Maria Ratai, PhD · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02843230 on ClinicalTrials.gov